<?xml version="1.0" encoding="UTF-8"?>
<protein>
  <version>3.5</version>
  <creation_date>2013-01-15 18:49:16 -0700</creation_date>
  <update_date>2013-05-27 11:32:59 -0600</update_date>
  <accession>HMDBP00184</accession>
  <secondary_accessions>
    <accession>5416</accession>
    <accession>HMDBP03431</accession>
  </secondary_accessions>
  <protein_type>Unknown</protein_type>
  <synonyms>
    <synonym>DHOdehase</synonym>
    <synonym>Dihydroorotate oxidase</synonym>
  </synonyms>
  <gene_name>DHODH</gene_name>
  <general_function>Involved in catalytic activity</general_function>
  <specific_function>Catalyzes the conversion of dihydroorotate to orotate with quinone as electron acceptor.
</specific_function>
  <pathways>
    <pathway>
      <name>Pyrimidine Metabolism</name>
      <smpdb_id>SMP00046</smpdb_id>
      <kegg_map_id>map00240</kegg_map_id>
    </pathway>
    <pathway>
      <name>UMP biosynthesis via de novo pathway</name>
      <smpdb_id/>
      <kegg_map_id/>
    </pathway>
    <pathway>
      <name>Pyrimidine metabolism</name>
      <smpdb_id/>
      <kegg_map_id>map00240</kegg_map_id>
    </pathway>
  </pathways>
  <metabolite_associations>
    <metabolite>
      <accession>HMDB03349</accession>
      <name>L-Dihydroorotic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00226</accession>
      <name>Orotic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01248</accession>
      <name>FAD</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00528</accession>
      <name>4,5-Dihydroorotic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01377</accession>
      <name>Oxygen</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01520</accession>
      <name>Flavin Mononucleotide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB03125</accession>
      <name>Hydrogen peroxide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15229</accession>
      <name>Leflunomide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15249</accession>
      <name>Atovaquone</name>
    </metabolite>
  </metabolite_associations>
  <go_classifications>
    <go_class>
      <category>function</category>
      <description>dihydroorotate oxidase activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>oxidoreductase activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>oxidoreductase activity, acting on the ch-ch group of donors</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>oxidoreductase activity, acting on the ch-ch group of donors, quinone or related compound as acceptor</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>dihydroorotate dehydrogenase activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>catalytic activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>cellular metabolic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>cellular aromatic compound metabolic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>nucleobase metabolic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>pyrimidine base metabolic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>pyrimidine base biosynthetic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>'de novo' pyrimidine base biosynthetic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>oxidation reduction</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>nitrogen compound metabolic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>cellular nitrogen compound metabolic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>nucleobase, nucleoside, nucleotide and nucleic acid metabolic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>nucleobase, nucleoside and nucleotide metabolic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>nucleoside phosphate metabolic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>nucleotide metabolic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>pyrimidine nucleotide metabolic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>pyrimidine nucleotide biosynthetic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>pyrimidine nucleoside monophosphate biosynthetic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>pyrimidine ribonucleoside monophosphate biosynthetic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>ump biosynthetic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>metabolic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>cell part</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>membrane</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>Cellular component</category>
      <description>integral to membrane</description>
      <go_id>GO:0016021</go_id>
    </go_class>
    <go_class>
      <category>Cellular component</category>
      <description>mitochondrial inner membrane</description>
      <go_id>GO:0005743</go_id>
    </go_class>
    <go_class>
      <category>Molecular function</category>
      <description>dihydroorotate dehydrogenase activity</description>
      <go_id>GO:0004152</go_id>
    </go_class>
    <go_class>
      <category>Molecular function</category>
      <description>dihydroorotate oxidase activity</description>
      <go_id>GO:0004158</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>'de novo' pyrimidine nucleobase biosynthetic process</description>
      <go_id>GO:0006207</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>'de novo' UMP biosynthetic process</description>
      <go_id>GO:0044205</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>positive regulation of apoptotic process</description>
      <go_id>GO:0043065</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>pyrimidine nucleoside biosynthetic process</description>
      <go_id>GO:0046134</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>regulation of mitochondrial fission</description>
      <go_id>GO:0090140</go_id>
    </go_class>
  </go_classifications>
  <subcellular_locations>
    <subcellular_location>Mitochondrion inner membrane</subcellular_location>
    <subcellular_location>Single-pass membrane protein (Potential)</subcellular_location>
  </subcellular_locations>
  <gene_properties>
    <chromosome_location>16</chromosome_location>
    <locus>16q22</locus>
    <gene_sequence>&gt;1188 bp
ATGGCGTGGAGACACCTGCAAAAGCGGGCCCAGGATGCTGTGATCATCCTGGGGGGAGGA
GGACTTCTCTTCGCCTCCTACCTGATGGCCACGGGAGATGAGCGTTTCTATGCTGAACAC
CTGATGCCGACTCTGCAGGGGCTGCTGGACCCGGAGTCAGCCCACAGACTGGCTGTTCGC
TTCACCTCCCTGGGGCTCCTTCCACGGGCCAGATTTCAAGACTCTGACATGCTGGAAGTG
AGAGTTCTGGGCCATAAATTCCGAAATCCAGTAGGAATTGCTGCAGGATTTGACAAGCAT
GGGGAAGCCGTGGACGGACTTTATAAGATGGGCTTTGGTTTTGTTGAGATAGGAAGTGTG
ACTCCAAAACCTCAGGAAGGAAACCCTAGACCCAGAGTCTTCCGCCTCCCTGAGGACCAA
GCTGTCATTAACAGGTATGGATTTAACAGTCACGGGCTTTCAGTGGTGGAACACAGGTTA
CGGGCCAGACAGCAGAAGCAGGCCAAGCTCACAGAAGATGGACTGCCTCTGGGGGTCAAC
TTGGGGAAGAACAAGACCTCAGTGGACGCCGCGGAGGACTACGCAGAAGGGGTGCGCGTA
CTGGGCCCCCTGGCCGACTACCTGGTGGTGAATGTGTCCAGCCCCAACACTGCCGGGCTG
CGGAGCCTTCAGGGAAAGGCCGAGCTGCGCCGCCTGCTGACCAAGGTGCTGCAGGAGAGG
GATGGCTTGCGGAGAGTGCACAGGCCGGCAGTCCTGGTGAAGATCGCTCCTGACCTCACC
AGCCAGGATAAGGAGGACATTGCCAGTGTGGTCAAAGAGTTGGGCATCGATGGGCTGATT
GTTACGAACACCACCGTGAGTCGCCCTGCGGGCCTCCAGGGTGCCCTGCGCTCTGAAACA
GGAGGGCTGAGTGGGAAGCCCCTCCGGGATTTATCAACTCAAACCATTCGGGAGATGTAT
GCACTCACCCAAGGCCGAGTTCCCATAATTGGGGTTGGTGGTGTGAGCAGCGGGCAGGAC
GCGCTGGAGAAGATCCGGGCAGGGGCCTCCCTGGTGCAGCTGTACACGGCCCTCACCTTC
TGGGGGCCACCCGTTGTGGGCAAAGTCAAGCGGGAACTGGAGGCCCTTCTGAAAGAGCAG
GGCTTTGGCGGAGTCACAGATGCCATTGGAGCAGATCATCGGAGGTGA</gene_sequence>
  </gene_properties>
  <protein_properties>
    <residue_number>395</residue_number>
    <molecular_weight>42866.93</molecular_weight>
    <theoretical_pi>9.667</theoretical_pi>
    <pfams>
      <pfam>
        <name>DHO_dh</name>
        <pfam_id>PF01180</pfam_id>
      </pfam>
    </pfams>
    <transmembrane_regions>
    </transmembrane_regions>
    <signal_regions>
    </signal_regions>
    <protein_sequence>&gt;Dihydroorotate dehydrogenase, mitochondrial
MAWRHLKKRAQDAVIILGGGGLLFASYLMATGDERFYAEHLMPTLQGLLDPESAHRLAVR
FTSLGLLPRARFQDSDMLEVRVLGHKFRNPVGIAAGFDKHGEAVDGLYKMGFGFVEIGSV
TPKPQEGNPRPRVFRLPEDQAVINRYGFNSHGLSVVEHRLRARQQKQAKLTEDGLPLGVN
LGKNKTSVDAAEDYAEGVRVLGPLADYLVVNVSSPNTAGLRSLQGKAELRRLLTKVLQER
DGLRRVHRPAVLVKIAPDLTSQDKEDIASVVKELGIDGLIVTNTTVSRPAGLQGALRSET
GGLSGKPLRDLSTQTIREMYALTQGRVPIIGVGGVSSGQDALEKIRAGASLVQLYTALTF
WGPPVVGKVKRELEALLKEQGFGGVTDAIGADHRR</protein_sequence>
  </protein_properties>
  <genbank_protein_id>158258018</genbank_protein_id>
  <uniprot_id>Q02127</uniprot_id>
  <uniprot_name>PYRD_HUMAN</uniprot_name>
  <pdb_ids>
    <pdb_id>1D3G</pdb_id>
    <pdb_id>1D3H</pdb_id>
    <pdb_id>2B0M</pdb_id>
    <pdb_id>2BXV</pdb_id>
    <pdb_id>2FPT</pdb_id>
    <pdb_id>2FPV</pdb_id>
    <pdb_id>2FPY</pdb_id>
    <pdb_id>2FQI</pdb_id>
    <pdb_id>2PRH</pdb_id>
    <pdb_id>2PRL</pdb_id>
    <pdb_id>2PRM</pdb_id>
    <pdb_id>2WV8</pdb_id>
    <pdb_id>3F1Q</pdb_id>
    <pdb_id>3FJ6</pdb_id>
    <pdb_id>3FJL</pdb_id>
    <pdb_id>3G0U</pdb_id>
    <pdb_id>3G0X</pdb_id>
    <pdb_id>3KVJ</pdb_id>
    <pdb_id>3KVK</pdb_id>
    <pdb_id>3KVL</pdb_id>
    <pdb_id>3KVM</pdb_id>
    <pdb_id>3U2O</pdb_id>
    <pdb_id>3ZWS</pdb_id>
    <pdb_id>3ZWT</pdb_id>
  </pdb_ids>
  <genbank_gene_id>AK292293</genbank_gene_id>
  <genecard_id>DHODH</genecard_id>
  <geneatlas_id>DHODH</geneatlas_id>
  <hgnc_id>HGNC:2867</hgnc_id>
  <general_references>
    <reference>
      <reference_text>Minet M, Dufour ME, Lacroute F: Cloning and sequencing of a human cDNA coding for dihydroorotate dehydrogenase by complementation of the corresponding yeast mutant. Gene. 1992 Nov 16;121(2):393-6.</reference_text>
      <pubmed_id>1446837</pubmed_id>
    </reference>
    <reference>
      <reference_text>Copeland RA, Davis JP, Dowling RL, Lombardo D, Murphy KB, Patterson TA: Recombinant human dihydroorotate dehydrogenase: expression, purification, and characterization of a catalytically functional truncated enzyme. Arch Biochem Biophys. 1995 Oct 20;323(1):79-86.</reference_text>
      <pubmed_id>7487077</pubmed_id>
    </reference>
    <reference>
      <reference_text>Ota T, Suzuki Y, Nishikawa T, Otsuki T, Sugiyama T, Irie R, Wakamatsu A, Hayashi K, Sato H, Nagai K, Kimura K, Makita H, Sekine M, Obayashi M, Nishi T, Shibahara T, Tanaka T, Ishii S, Yamamoto J, Saito K, Kawai Y, Isono Y, Nakamura Y, Nagahari K, Murakami K, Yasuda T, Iwayanagi T, Wagatsuma M, Shiratori A, Sudo H, Hosoiri T, Kaku Y, Kodaira H, Kondo H, Sugawara M, Takahashi M, Kanda K, Yokoi T, Furuya T, Kikkawa E, Omura Y, Abe K, Kamihara K, Katsuta N, Sato K, Tanikawa M, Yamazaki M, Ninomiya K, Ishibashi T, Yamashita H, Murakawa K, Fujimori K, Tanai H, Kimata M, Watanabe M, Hiraoka S, Chiba Y, Ishida S, Ono Y, Takiguchi S, Watanabe S, Yosida M, Hotuta T, Kusano J, Kanehori K, Takahashi-Fujii A, Hara H, Tanase TO, Nomura Y, Togiya S, Komai F, Hara R, Takeuchi K, Arita M, Imose N, Musashino K, Yuuki H, Oshima A, Sasaki N, Aotsuka S, Yoshikawa Y, Matsunawa H, Ichihara T, Shiohata N, Sano S, Moriya S, Momiyama H, Satoh N, Takami S, Terashima Y, Suzuki O, Nakagawa S, Senoh A, Mizoguchi H, Goto Y, Shimizu F, Wakebe H, Hishigaki H, Watanabe T, Sugiyama A, Takemoto M, Kawakami B, Yamazaki M, Watanabe K, Kumagai A, Itakura S, Fukuzumi Y, Fujimori Y, Komiyama M, Tashiro H, Tanigami A, Fujiwara T, Ono T, Yamada K, Fujii Y, Ozaki K, Hirao M, Ohmori Y, Kawabata A, Hikiji T, Kobatake N, Inagaki H, Ikema Y, Okamoto S, Okitani R, Kawakami T, Noguchi S, Itoh T, Shigeta K, Senba T, Matsumura K, Nakajima Y, Mizuno T, Morinaga M, Sasaki M, Togashi T, Oyama M, Hata H, Watanabe M, Komatsu T, Mizushima-Sugano J, Satoh T, Shirai Y, Takahashi Y, Nakagawa K, Okumura K, Nagase T, Nomura N, Kikuchi H, Masuho Y, Yamashita R, Nakai K, Yada T, Nakamura Y, Ohara O, Isogai T, Sugano S: Complete sequencing and characterization of 21,243 full-length human cDNAs. Nat Genet. 2004 Jan;36(1):40-5. Epub 2003 Dec 21.</reference_text>
      <pubmed_id>14702039</pubmed_id>
    </reference>
    <reference>
      <reference_text>Gerhard DS, Wagner L, Feingold EA, Shenmen CM, Grouse LH, Schuler G, Klein SL, Old S, Rasooly R, Good P, Guyer M, Peck AM, Derge JG, Lipman D, Collins FS, Jang W, Sherry S, Feolo M, Misquitta L, Lee E, Rotmistrovsky K, Greenhut SF, Schaefer CF, Buetow K, Bonner TI, Haussler D, Kent J, Kiekhaus M, Furey T, Brent M, Prange C, Schreiber K, Shapiro N, Bhat NK, Hopkins RF, Hsie F, Driscoll T, Soares MB, Casavant TL, Scheetz TE, Brown-stein MJ, Usdin TB, Toshiyuki S, Carninci P, Piao Y, Dudekula DB, Ko MS, Kawakami K, Suzuki Y, Sugano S, Gruber CE, Smith MR, Simmons B, Moore T, Waterman R, Johnson SL, Ruan Y, Wei CL, Mathavan S, Gunaratne PH, Wu J, Garcia AM, Hulyk SW, Fuh E, Yuan Y, Sneed A, Kowis C, Hodgson A, Muzny DM, McPherson J, Gibbs RA, Fahey J, Helton E, Ketteman M, Madan A, Rodrigues S, Sanchez A, Whiting M, Madari A, Young AC, Wetherby KD, Granite SJ, Kwong PN, Brinkley CP, Pearson RL, Bouffard GG, Blakesly RW, Green ED, Dickson MC, Rodriguez AC, Grimwood J, Schmutz J, Myers RM, Butterfield YS, Griffith M, Griffith OL, Krzywinski MI, Liao N, Morin R, Palmquist D, Petrescu AS, Skalska U, Smailus DE, Stott JM, Schnerch A, Schein JE, Jones SJ, Holt RA, Baross A, Marra MA, Clifton S, Makowski KA, Bosak S, Malek J: The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). Genome Res. 2004 Oct;14(10B):2121-7.</reference_text>
      <pubmed_id>15489334</pubmed_id>
    </reference>
    <reference>
      <reference_text>Knecht W, Bergjohann U, Gonski S, Kirschbaum B, Loffler M: Functional expression of a fragment of human dihydroorotate dehydrogenase by means of the baculovirus expression vector system, and kinetic investigation of the purified recombinant enzyme. Eur J Biochem. 1996 Aug 15;240(1):292-301.</reference_text>
      <pubmed_id>8925840</pubmed_id>
    </reference>
    <reference>
      <reference_text>Liu S, Neidhardt EA, Grossman TH, Ocain T, Clardy J: Structures of human dihydroorotate dehydrogenase in complex with antiproliferative agents. Structure. 2000 Jan 15;8(1):25-33.</reference_text>
      <pubmed_id>10673429</pubmed_id>
    </reference>
    <reference>
      <reference_text>Ng SB, Buckingham KJ, Lee C, Bigham AW, Tabor HK, Dent KM, Huff CD, Shannon PT, Jabs EW, Nickerson DA, Shendure J, Bamshad MJ: Exome sequencing identifies the cause of a mendelian disorder.  Nat Genet. 2010 Jan;42(1):30-5. Epub 2009 Nov 13.</reference_text>
      <pubmed_id>19915526</pubmed_id>
    </reference>
  </general_references>
  <metabolite_references>
    <metabolite_reference>
      <metabolite>
        <name>Flavin Mononucleotide</name>
        <accession>HMDB01520</accession>
      </metabolite>
      <reference>
        <reference_text>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there?  Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</reference_text>
        <pubmed_id>17139284</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Flavin Mononucleotide</name>
        <accession>HMDB01520</accession>
      </metabolite>
      <reference>
        <reference_text>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets.  Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</reference_text>
        <pubmed_id>17016423</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Flavin Mononucleotide</name>
        <accession>HMDB01520</accession>
      </metabolite>
      <reference>
        <reference_text>Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank.  Nucleic Acids Res. 2000 Jan 1;28(1):235-42.</reference_text>
        <pubmed_id>10592235</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Leflunomide</name>
        <accession>HMDB15229</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Leflunomide</name>
        <accession>HMDB15229</accession>
      </metabolite>
      <reference>
        <reference_text>Goldenberg MM: Leflunomide, a novel immunomodulator for the treatment of active rheumatoid arthritis. Clin Ther. 1999 Nov;21(11):1837-52; discussion 1821.</reference_text>
        <pubmed_id>10890256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Leflunomide</name>
        <accession>HMDB15229</accession>
      </metabolite>
      <reference>
        <reference_text>Prakash A, Jarvis B: Leflunomide: a review of its use in active rheumatoid arthritis.  Drugs. 1999 Dec;58(6):1137-64.</reference_text>
        <pubmed_id>10651393</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Leflunomide</name>
        <accession>HMDB15229</accession>
      </metabolite>
      <reference>
        <reference_text>Li EK, Tam LS, Tomlinson B: Leflunomide in the treatment of rheumatoid arthritis.  Clin Ther. 2004 Apr;26(4):447-59.</reference_text>
        <pubmed_id>15189743</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Leflunomide</name>
        <accession>HMDB15229</accession>
      </metabolite>
      <reference>
        <reference_text>Wozel G, Pfeiffer C: [Leflunomide--a new drug for pharmacological immunomodulation].  Hautarzt. 2002 May;53(5):309-15.</reference_text>
        <pubmed_id>12063741</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Leflunomide</name>
        <accession>HMDB15229</accession>
      </metabolite>
      <reference>
        <reference_text>Sanders S, Harisdangkul V: Leflunomide for the treatment of rheumatoid arthritis and autoimmunity.  Am J Med Sci. 2002 Apr;323(4):190-3.</reference_text>
        <pubmed_id>12003373</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Leflunomide</name>
        <accession>HMDB15229</accession>
      </metabolite>
      <reference>
        <reference_text>Breedveld FC, Dayer JM: Leflunomide: mode of action in the treatment of rheumatoid arthritis.  Ann Rheum Dis. 2000 Nov;59(11):841-9.</reference_text>
        <pubmed_id>11053058</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Leflunomide</name>
        <accession>HMDB15229</accession>
      </metabolite>
      <reference>
        <reference_text>Reitzik M, Lownie JF: Familial polyostotic fibrous dysplasia.  Oral Surg Oral Med Oral Pathol. 1975 Dec;40(6):769-74.</reference_text>
        <pubmed_id>1060033</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Leflunomide</name>
        <accession>HMDB15229</accession>
      </metabolite>
      <reference>
        <reference_text>Herrmann ML, Schleyerbach R, Kirschbaum BJ: Leflunomide: an immunomodulatory drug for the treatment of rheumatoid arthritis and other autoimmune diseases. Immunopharmacology. 2000 May;47(2-3):273-89.</reference_text>
        <pubmed_id>10878294</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Leflunomide</name>
        <accession>HMDB15229</accession>
      </metabolite>
      <reference>
        <reference_text>Schattenkirchner M: The use of leflunomide in the treatment of rheumatoid arthritis: an experimental and clinical review. Immunopharmacology. 2000 May;47(2-3):291-8.</reference_text>
        <pubmed_id>10878295</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Leflunomide</name>
        <accession>HMDB15229</accession>
      </metabolite>
      <reference>
        <reference_text>Fox RI: Mechanism of action of leflunomide in rheumatoid arthritis.  J Rheumatol Suppl. 1998 Jul;53:20-6.</reference_text>
        <pubmed_id>9666414</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Leflunomide</name>
        <accession>HMDB15229</accession>
      </metabolite>
      <reference>
        <reference_text>Fukushima R, Kanamori S, Hirashiba M, Hishikawa A, Muranaka RI, Kaneto M, Nakamura K, Kato I: Teratogenicity study of the dihydroorotate-dehydrogenase inhibitor and protein tyrosine kinase inhibitor Leflunomide in mice. Reprod Toxicol. 2007 Nov-Dec;24(3-4):310-6. Epub 2007 May 18.</reference_text>
        <pubmed_id>17604599</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Atovaquone</name>
        <accession>HMDB15249</accession>
      </metabolite>
      <reference>
        <reference_text>Knecht W, Henseling J, Loffler M: Kinetics of inhibition of human and rat dihydroorotate dehydrogenase by atovaquone, lawsone derivatives, brequinar sodium and polyporic acid. Chem Biol Interact. 2000 Jan 3;124(1):61-76.</reference_text>
        <pubmed_id>10658902</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Atovaquone</name>
        <accession>HMDB15249</accession>
      </metabolite>
      <reference>
        <reference_text>Hansen M, Le Nours J, Johansson E, Antal T, Ullrich A, Loffler M, Larsen S: Inhibitor binding in a class 2 dihydroorotate dehydrogenase causes variations in the membrane-associated N-terminal domain. Protein Sci. 2004 Apr;13(4):1031-42.</reference_text>
        <pubmed_id>15044733</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Atovaquone</name>
        <accession>HMDB15249</accession>
      </metabolite>
      <reference>
        <reference_text>Ittarat I, Asawamahasakda W, Bartlett MS, Smith JW, Meshnick SR: Effects of atovaquone and other inhibitors on Pneumocystis carinii dihydroorotate dehydrogenase. Antimicrob Agents Chemother. 1995 Feb;39(2):325-8.</reference_text>
        <pubmed_id>7726490</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Atovaquone</name>
        <accession>HMDB15249</accession>
      </metabolite>
      <reference>
        <reference_text>Seymour KK, Lyons SD, Phillips L, Rieckmann KH, Christopherson RI: Cytotoxic effects of inhibitors of de novo pyrimidine biosynthesis upon Plasmodium falciparum. Biochemistry. 1994 May 3;33(17):5268-74.</reference_text>
        <pubmed_id>7909690</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Atovaquone</name>
        <accession>HMDB15249</accession>
      </metabolite>
      <reference>
        <reference_text>Seymour KK, Yeo AE, Rieckmann KH, Christopherson RI: dCTP levels are maintained in Plasmodium falciparum subjected to pyrimidine deficiency or excess. Ann Trop Med Parasitol. 1997 Sep;91(6):603-9.</reference_text>
        <pubmed_id>9425362</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Atovaquone</name>
        <accession>HMDB15249</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
  </metabolite_references>
</protein>
